Guardant Health, Eurofins Genomics & FOUNDATION MEDICINE, INC. are dominating the Global Circulating Tumor Cells (CTC) Liquid Biopsy Market in 2022

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market is expected to grow with the CAGR of 25.3% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market

The global circulating tumor cells (CTC) liquid biopsy market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global circulating tumor cells (CTC) liquid biopsy market are introducing strong range of applications and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In November, Guardant Health announced that it has participated in Stifel Healthcare Conference. This has helped the company to furnish correct knowledge about its products in the market.

Guardant Health is the dominating player in global circulating tumor cells (CTC) liquid biopsy market. The other key players existing in the market includes Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc.,  ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.

Circulating Tumor Cells (CTC) Liquid Biopsy MarketGuardant Health

Guardant Health was established in 2013, and headquartered in California, U.S. The company is engaged in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company also provides various SERVICE categories including Treatment Selection, Residual Disease & Recurrence Monitoring, Cancer Screening & Biopharma Solutions in which Treatment Selection, Residual Disease & Recurrence Monitoring is the market focused category.

For instance,

  • In November 2021, Guardant Health announced that it has entered into partnership with The Royal Marsden NHS Foundation Trust to establish an in-house liquid biopsy testing service for cancer diagnosis. This will help the company to expand its presence in the market.

The company has wide presence in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The company has subsidiary such as Bellwether Bio, Inc. (U.S.).

Eurofins Genomics

Eurofins Genomics was established in 1990, and headquartered in Ebersberg, Germany. The company is provider of genomic services and is globally known for its innovative and customised technologies in the life science industries and academic research institutions. The company also provides services categories including DNA & RAN Oligonucleotides, Custom DNA Sequencing, Next Generation Sequencing, Gene Synthesis/Molecular Biology & Genotyping & Gene Expression in which Next Generation Sequencing is the market focused category.

  • In March 2016, Eurofins Genomics announced that it has opened new state of the art manufacturing and services facility in Kentucky. U.S. This has helped the company to expand its geographic presence in the market.

The company has wide presence in North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

FOUNDATION MEDICINE, INC.

FOUNDATION MEDICINE, INC. was established in 2010, and headquartered in Massachusetts, U.S. The company is engaged in offering a proven portfolio of comprehensive genomic profiling products that help physicians make more informed care decisions. The company provides various product categories including FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme, PD-L1 IHC Testing in which the market focus products lie under FoundationOne CDx.

  • In August 2021, FOUNDATION MEDICINE, INC. announced that it has entered into partnership with Epic to integrate its genomic profiling with Epic’s electronic medical record system. This will help the company to support oncology practices in advanced manner.

The company has wide presence in North America, Europe.